Trial Profile
Combined Phase I-Phase II Study of Autologous CD8+ T-cells Transiently Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen in Patients With Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Mar 2022
Price :
$35
*
At a glance
- Drugs Descartes 08 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Cartesian Therapeutics
- 10 Mar 2022 Status changed from recruiting to completed.
- 09 Feb 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2022.
- 09 Feb 2021 Planned primary completion date changed from 26 Dec 2020 to 26 Dec 2021.